OncoMatch

OncoMatch/Clinical Trials/NCT07660627

Determining Minimal Residual Disease Using ctDNA Deep Sequencing

Is NCT07660627 recruiting? Yes, currently enrolling (Sep 2026). This NA trial studies non-drug interventions for esophageal adenocarcinoma.

NARecruitingMasaryk Memorial Cancer InstituteNCT07660627Data as of Sep 2026Location: Czechia
Check if I qualify

Extracted eligibility criteria

Cancer type

Esophageal Carcinoma

Gastric Cancer

Pancreatic Cancer

Disease stage

Required: Stage 0, I, II

stage 0-2; locally advanced, potentially operable disease; metastatic disease

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT07660627 currently recruiting?

Yes, this trial is currently recruiting patients.

What disease stage is eligible?

Stage 0 or I or II is required.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify